Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Lesinski, Gregory B ^a   Zimmerer, Jason M ^a   Kreiner, Melanie ^a   Trefry, John ^a   Bill, Matthew A ^a   Young, Gregory S ^a   Becknell, Brian ^a   Carson III, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERFERON; RETROVIRUS VECTOR; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TYROSINE; ALPHA2B INTERFERON; SOCS1 PROTEIN, HUMAN; SOCS3 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN;

ARTICLE; EMBRYO; EXPRESSION VECTOR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOREACTIVITY; MELANOCYTE; MELANOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; MELANOMA; METABOLISM; PHOSPHORYLATION;

HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; INTERFERON-GAMMA; MELANOMA; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSFECTION;

EID: 77950650093     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-142     Document Type: Article

References (44)

1. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6(11):836-848. 10.1038/nri1961, 17063185.
2. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005, 6(7):722-729. 10.1038/ni1213, 15951814.
3. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998, 95(13):7556-7561. 10.1073/pnas.95.13.7556, 22681, 9636188.
4. Agarwala SS, Kirkwood JM. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer 2003, 97(1):121-127. 10.1002/cncr.11041, 12491513.
5. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18(12):2444-2458.
6. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology 1996, 14(1):7-17.
7. Legha SS. Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer 1986, 57(8 Suppl):1675-1677. 10.1002/1097-0142(19860415)57:8+<1675::AID-CNCR2820571307>3.0.CO;2-I, 3512072.
8. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999, 17(9):2859-2867.
9. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354(7):709-718. 10.1056/NEJMoa053007, 16481638.
10. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury RA, et al. The anti-tumor effects of interferon-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003, 112(2):170-180. 164283, 12865406.
11. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24(19):3164-3171. 10.1200/JCO.2005.05.2498, 16809739.
12. Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002, 21(16):2504-2512. 10.1038/sj.onc.1205341, 11971185.
13. Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000, 19(21):2505-2510. 10.1038/sj.onc.1203480, 10851049.
14. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000, 85(5):720-725. 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O, 10699955.
15. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21(8):1251-1262. 10.1038/sj.onc.1205179, 11850845.
16. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421. 10.1126/science.8197455, 8197455.
17. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005, 5(5):375-386. 10.1038/nri1604, 15864272.
18. Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X, Crespin TR, et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res 2007, 13(17):5010-5019. 10.1158/1078-0432.CCR-06-3092, 17785551.
19. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J 1995, 14(12):2816-2826. 398400, 7796808.
20. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002, 2(6):410-416.
21. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem 2004, 279(2):821-824. 10.1074/jbc.R300030200, 14607831.
22. Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C, Luger TA, Bohm M. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004, 123(4):737-745. 10.1111/j.0022-202X.2004.23408.x, 15373779.
23. Fojtova M, Boudny V, Kovarik A, Lauerova L, Adamkova L, Souckova K, Jarkovsky J, Kovarik J. Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. Br J Cancer 2007, 97(2):231-237. 10.1038/sj.bjc.6603849, 2360293, 17579625.
24. Komyod W, Bohm M, Metze D, Heinrich PC, Behrmann I. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 2007, 5(3):271-281. 10.1158/1541-7786.MCR-06-0274, 17374732.
25. Kovarik A, Fojtova M, Boudny V, Adamkova L, Lauerova L, Kovarik J. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. Melanoma Res 2005, 15(6):481-488. 10.1097/00008390-200512000-00001, 16314732.
26. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997, 7(Suppl 2):S35-42.
27. Gregorieff A, Pyronnet S, Sonenberg N, Veillette A. Regulation of SOCS-1 expression by translational repression. J Biol Chem 2000, 275(28):21596-21604. 10.1074/jbc.M910087199, 10764816.
28. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker MJ, Carson WE. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon alfa immunotherapy. J Natl Cancer Inst 2004, 96:1331-1342.
29. Lesinski GB, Badgwell B, Zimmerer J, Crespin T, Hu Y, Abood G, Carson WE. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J Immunol 2004, 172(12):7368-7376.
30. Becknell B, Trotta R, Yu J, Ding W, Mao HC, Hughes T, Marburger T, Caligiuri MA. Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector. J Immunol Methods 2005, 296(1-2):115-123. 10.1016/j.jim.2004.11.012, 15680156.
31. Zimmerer JM, Lesinski GB, Kondadasula SV, Karpa VI, Lehman A, Raychaudhury A, Becknell B, Carson WE. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol 2007, 178(8):4832-4845.
32. Kramer C. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 1956, 12:309-310.
33. Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 2008, 19(4):341-350. 10.1016/j.semcdb.2008.06.005, 18621135.
34. Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 2005, 65(8):3447-3453.
35. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997, 272(45):28779-28785. 10.1074/jbc.272.45.28779, 9353349.
36. Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, Borden EC. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (stat1). J Interferon Cytokine Res 2002, 22(5):603-613. 10.1089/10799900252982089, 12060499.
37. Jackson DP, Watling D, Rogers NC, Banks RE, Kerr IM, Selby PJ, Patel PM. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 2003, 13(3):219-229. 10.1097/00008390-200306000-00001, 12777975.
38. Tokita T, Maesawa C, Kimura T, Kotani K, Takahashi K, Akasaka T, Masuda T. Methylation status of the SOCS3 gene in human malignant melanomas. Int J Oncol 2007, 30(3):689-694.
39. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 2002, 100(8):2926-2931. 10.1182/blood-2002-01-0073, 12351404.
40. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, Wasik M, Odum N. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005, 19(2):209-213. 10.1038/sj.leu.2403610, 15618960.
41. Zitzmann K, Brand S, De Toni EN, Baehs S, Goke B, Meinecke J, Spottl G, Meyer HH, Auernhammer CJ. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 2007, 67(10):5025-5032. 10.1158/0008-5472.CAN-06-2575, 17510435.
42. Takahashi Y, Kaneda H, Takasuka N, Hattori K, Nishikawa M, Takakura Y. Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells. Cancer Sci 2008, 99(8):1650-1655. 10.1111/j.1349-7006.2008.00850.x, 18754879.
43. Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, Sawaya R, Huang S. Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res 2008, 68(23):9634-9642. 10.1158/0008-5472.CAN-08-1429, 19047140.
44. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 2004, 22(12):1546-1553. 10.1038/nbt1035, 15558048.